ERBB2 and neoplasm: Additionally, monoclonal antibody-based therapies, such as trastuzumab, have shown limited clinical benefits in HER2-mutant NSCLC when used as monotherapy (Cooper and Gainor, 2022), likely due to insufficient tumor penetration and inadequate downstream signaling blockade.